List of Excipients in Branded Drug HEPARIN SODIUM AND DEXTROSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	HEPARIN SODIUM AND DEXTROSE	heparin sodium	0409-7793	ANHYDROUS CITRIC ACID
Hospira Inc	HEPARIN SODIUM AND DEXTROSE	heparin sodium	0409-7793	DEXTROSE MONOHYDRATE
Hospira Inc	HEPARIN SODIUM AND DEXTROSE	heparin sodium	0409-7793	SODIUM METABISULFITE
Hospira Inc	HEPARIN SODIUM AND DEXTROSE	heparin sodium	0409-7793	TRISODIUM CITRATE DIHYDRATE

Heparin Sodium and Dextrose Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 29, 2026

Heparin sodium and dextrose injection is an established intravenous anticoagulant product in which dextrose functions primarily as the infusion vehicle. The active pharmaceutical ingredient, heparin sodium, has no meaningful composition-of-matter exclusivity remaining. Commercial differentiation depends on container technology, concentration selection, stability, supply reliability, manufacturing controls, and hospital workflow integration.

The strongest opportunities are ready-to-use premixed presentations, preservative-free and DEHP-free packaging, improved particulate and extractables control, standardized concentrations, and reliable supply during hospital shortages. Biosimilar competition is not the principal risk. Generic and authorized-generic competition is.

What is heparin sodium and dextrose injection?

Heparin sodium and dextrose injection is a sterile intravenous solution containing unfractionated heparin sodium in a dextrose-containing carrier, commonly 5% dextrose in water. It is used when systemic anticoagulation is required and is administered by intravenous infusion or injection under clinical supervision. Product labels describe uses including prevention and treatment of venous thrombosis, pulmonary embolism, arterial thromboembolism, and selected cardiovascular indications.[1]

The product is not a combination in which dextrose adds pharmacological activity. Dextrose provides:

• An isotonic or near-isotonic infusion vehicle, depending on product concentration.
• A ready-to-administer diluent.
• A way to reduce bedside preparation.
• A formulation platform compatible with hospital infusion systems.

The relevant pharmaceutical development challenge is maintaining heparin potency, solution clarity, container compatibility, sterility, and dose accuracy over the labeled shelf life.

What FDA regulatory status applies to heparin sodium and dextrose?

Heparin sodium and dextrose injection is an FDA-approved prescription sterile injectable product. The regulatory pathway depends on the proposed presentation and reference product. A manufacturer may pursue an abbreviated application where the product qualifies as therapeutically equivalent to an approved reference product, or may require another 505(b) pathway when formulation, container, concentration, or clinical characteristics create differences that cannot be addressed through a conventional abbreviated application.[2]

Heparin sodium is a complex biological mixture derived from animal tissue, generally porcine intestinal mucosa. It is not a single molecular entity. The product therefore requires tight control of source material, identity, potency, molecular-weight distribution, impurities, and contamination risks.

Is heparin a biosimilar?

No. Heparin sodium products are not generally regulated as biosimilars under the FDA biosimilar pathway used for protein and other biological products. Heparin is a heterogeneous polysaccharide mixture with biological activity and source-dependent characteristics. The principal competitive pathway is generic or follow-on injectable approval, not biosimilar interchangeability.

The regulatory difficulty remains substantial. FDA has required extensive controls for heparin starting material and has taken specific action against oversulfated chondroitin sulfate contamination and related quality risks.[3]

What patents protect heparin sodium and dextrose injection?

No active composition-of-matter patent is expected to block development of heparin sodium in dextrose. Heparin sodium, dextrose, intravenous infusion, and the basic anticoagulant use are longstanding technologies.

Protection category	Commercial relevance	Expected exclusivity position
Heparin sodium composition	Low	Historical patents expired
Dextrose carrier	Low	Historical patents expired
Basic anticoagulant use	Low	Long-established clinical use
Premixed IV formulation	Moderate	Potential formulation or process claims may exist, but basic formulation is mature
Flexible infusion container	Moderate to high	Device, material, and manufacturing patents may apply
Sterile manufacturing process	Moderate	Process patents and trade secrets may affect differentiation
Product-specific concentration	Low to moderate	May support regulatory differentiation but rarely creates durable exclusion alone
Closed-system transfer or connector	Moderate	Device and combination-product rights may apply
Stability-enhancing packaging	Moderate	Potential claims around container, oxygen control, or adsorption
Hospital workflow software	Low to moderate	Separate device or software rights may apply

The main patent risk is therefore peripheral. A sponsor must review patents covering flexible bags, multilayer films, ports, connectors, overwraps, sterilization, filling systems, and admixture or infusion devices.

What is the Orange Book status of heparin sodium and dextrose?

The Orange Book is not expected to provide a meaningful barrier for the active ingredients themselves. Older injectable products may have product-specific listings, but the commercial question is whether any listed patent is relevant to the proposed concentration, container, route, and labeling.

For a generic applicant, the relevant review should include:

1. The current Orange Book listing for the selected reference product.
2. Approved labeling and concentration.
3. Patent and exclusivity entries associated with the reference product.
4. Any FDA patent-certification requirements.
5. Paragraph IV risk, if a listed patent remains relevant.
6. Patent families covering the container or delivery system outside the Orange Book.

A basic heparin sodium in dextrose product is unlikely to face a meaningful Paragraph IV barrier from active ingredient patents. Paragraph IV exposure is more plausible where a reference product has a proprietary container, formulation, delivery system, or specific method-of-use listing.

When does heparin sodium and dextrose lose exclusivity?

The underlying drug technology has already lost exclusivity. Heparin sodium and dextrose are established generic ingredients, and no new chemical entity exclusivity applies to the combination.

Exclusivity type	Applicability
New chemical entity exclusivity	None expected
New clinical investigation exclusivity	Not inherent to the established product
Orphan-drug exclusivity	Not expected
Pediatric exclusivity	No general product-level assumption
Reference-product patent exclusivity	Must be checked by product and presentation
Trade-secret protection	Potentially important for manufacturing and sourcing
Container patent protection	Potentially relevant to a specific presentation

Generic entry can occur after FDA approval if the applicant satisfies quality, bioequivalence or equivalence, labeling, manufacturing, and facility requirements. In practice, supply qualification and hospital contracting may delay commercial uptake after approval.

What formulation patents protect heparin sodium in dextrose?

Potential formulation claims may cover:

• Specific heparin concentrations.
• Defined dextrose concentrations.
• pH ranges.
• Osmolality limits.
• Preservative-free compositions.
• Low-oxygen or low-peroxide packaging.
• Reduced adsorption to container surfaces.
• Stability during terminal sterilization.
• Compatibility with infusion tubing and pumps.
• Control of particulate matter and visible fibers.
• Container overwraps that limit moisture or oxygen transfer.

Most basic formulations are likely vulnerable to invalidity or narrow claim scope because the components and route are old. A commercially meaningful claim would need a specific technical result, such as improved stability, reduced potency loss, reduced impurity formation, or a non-obvious container interaction.

Which excipients are commercially relevant?

The product has a narrow excipient profile. Dextrose is the principal excipient, while water for injection adjusts volume. Some presentations may include pH-adjusting agents or other formulation components, depending on the approved product.

The strongest excipient strategy is usually excipient minimization rather than excipient expansion:

• Avoid unnecessary preservatives in intravenous products.
• Minimize formulation variables that complicate equivalence.
• Control dextrose degradation products.
• Evaluate interaction between heparin and container surfaces.
• Confirm compatibility with common infusion tubing.
• Maintain a formulation suitable for terminal sterilization where feasible.

Adding novel excipients may create regulatory complexity without creating a defensible commercial advantage.

How strong is the patent estate for heparin sodium and dextrose?

The drug substance and basic formulation estate is weak from an exclusion standpoint. The manufacturing and packaging estate can be stronger.

Drug substance position

Heparin sodium is a mature active ingredient. The principal barriers are quality and sourcing, not patent exclusion. A supplier must control:

• Animal-source qualification.
• Traceability of mucosal tissue.
• Viral and adventitious-agent controls.
• Molecular-weight distribution.
• Potency assay performance.
• Oversulfated contaminant detection.
• Residual solvents, metals, proteins, and microbial impurities.

These controls can create meaningful entry costs even where patents do not.

Finished-dose position

The finished-dose product can be differentiated through:

• Concentration standardization.
• Ready-to-use bags.
• Larger institutional presentations.
• Low-volume presentations for fluid-restricted patients.
• Reduced overfill.
• Improved labeling and barcode readability.
• Tamper-evident packaging.
• Compatibility with automated dispensing and smart-pump systems.

These attributes may be difficult to patent broadly but can support contracting advantages and customer retention.

What generic entry risks exist?

The main generic entry risks are price erosion, contract displacement, shortage-driven substitution, and manufacturing failures.

Risk	Likely impact
Additional injectable manufacturers	Moderate to high price pressure
Authorized generic launch	High impact on price and hospital contracts
Hospital pharmacy bulk purchasing	High impact on margins
Supply interruption	High operational risk
Heparin-source contamination	High regulatory and recall risk
Container incompatibility	Moderate quality risk
Concentration errors	High patient-safety risk
Labeling or barcode failure	Moderate procurement risk
Limited manufacturing sites	High concentration risk

A generic entrant does not need a superior molecule. It needs reliable approval, validated sterile manufacturing, dependable heparin sourcing, competitive pricing, and a hospital-ready supply chain.

Which companies compete in heparin sodium injectable products?

Competition generally comes from established injectable manufacturers, hospital-supply companies, and suppliers with heparin drug-substance capabilities. Relevant commercial participants have included Pfizer, Fresenius Kabi, Baxter, B. Braun, Hikma, Sagent Pharmaceuticals, and other regional injectable manufacturers, depending on the specific presentation and market.

The competitive set changes by:

• Country.
• Heparin concentration.
• Container size.
• Dextrose concentration.
• Premixed versus pharmacy-compounded format.
• Availability during shortage periods.
• Contracting arrangements with group purchasing organizations.

The most important competitor may be a pharmacy-compounded product or an alternative heparin presentation rather than an identical premixed bag.

What commercial opportunities exist in excipient and packaging strategy?

Ready-to-use premixed bags

Premixed bags reduce pharmacy labor, preparation errors, and handling requirements. A manufacturer can target intensive care units, operating rooms, cardiac catheterization laboratories, and emergency departments.

The value proposition is strongest where hospitals prioritize standardized concentrations and reduced manipulation of high-alert anticoagulants.

Preservative-free and DEHP-free presentations

Preservative-free products are attractive for intravenous use because they reduce concerns about preservative exposure. DEHP-free and latex-free packaging can support institutional procurement requirements and use in sensitive patient populations.

These attributes are more likely to support premium contracting than patent exclusivity.

Concentration and volume segmentation

A product portfolio can include:

• Standard institutional concentrations.
• Small-volume bags for patients with fluid restrictions.
• Higher-concentration presentations for specialized infusion protocols.
• Larger-volume bags for continuous anticoagulation.
• Labeling designed for high-risk medication verification.

Each additional concentration raises manufacturing, inventory, and medication-error complexity. The commercial benefit must justify the portfolio expansion.

Container and stability engineering

A differentiated product can focus on:

• Low-sorption film structures.
• Reduced oxygen and moisture transmission.
• Improved port integrity.
• Low extractables and leachables.
• Better resistance to overwrap damage.
• Clearer visual inspection.
• Longer validated shelf life.
• More reliable performance under refrigerated or controlled-room-temperature storage.

These improvements can generate procurement value even where they do not create broad patent protection.

What manufacturing and IP barriers affect market entry?

The most important barriers are operational:

1. Qualified heparin sodium supply.
2. Validated sterile filling and terminal sterilization.
3. Control of potency and molecular-weight distribution.
4. Container-closure integrity.
5. Extractables and leachables qualification.
6. Stability in the final container.
7. Inspection and particulate control.
8. Reliable supply during hospital demand spikes.
9. FDA-compliant facility performance.
10. Contracting access with hospitals and group purchasing organizations.

Trade secrets may be more valuable than patents in this market. Examples include sourcing qualification, impurity-control methods, filling parameters, sterilization cycles, and packaging specifications.

What litigation and settlement risks affect the product?

No major, product-defining patent litigation trend is inherent to the basic heparin sodium and dextrose formulation. Litigation exposure is more likely to arise from:

• Patent disputes over proprietary infusion bags or connectors.
• Product-liability claims involving dosing errors.
• Contamination or potency failures.
• Manufacturing-process disputes.
• Supply agreements and exclusivity contracts.
• Regulatory actions involving quality systems.

Settlement agreements could affect launch timing where a generic challenges a listed patent for a specific reference product. Such agreements must be reviewed individually. There is no general settlement date that governs the entire heparin sodium and dextrose market.

How does heparin sodium and dextrose compare with competing anticoagulants?

Product	Primary competitive advantage	Main limitation
Heparin sodium in dextrose	Rapid titration, established reversal with protamine, hospital familiarity	Monitoring burden and bleeding risk
Heparin sodium in saline	Broad institutional use and formulation familiarity	Does not provide dextrose vehicle
Low-molecular-weight heparin	More predictable pharmacokinetics and subcutaneous administration	Less readily titratable and more difficult to reverse
Direct oral anticoagulants	Oral administration and outpatient convenience	Limited suitability for unstable hospitalized patients
Bivalirudin or other direct thrombin inhibitors	Use in selected heparin-induced thrombocytopenia or procedural settings	Higher cost and narrower use

Heparin sodium and dextrose remains commercially relevant in acute-care settings because of its rapid onset, titratability, established protocols, and reversibility.

What revenue exposure and market-entry scenarios should investors model?

Public sources generally do not disclose revenue for the heparin sodium and dextrose presentation separately. Commercial exposure should therefore be modeled from hospital volume, contract price, concentration mix, and supply availability rather than branded product revenue.

Scenario 1: Commodity generic entry

Two or more suppliers compete on price. Margins decline, and procurement contracts determine share. Packaging differentiation has limited value unless it reduces hospital labor or medication errors.

Scenario 2: Shortage-resilient supplier

A manufacturer with qualified drug-substance sources and redundant sterile capacity wins share during supply interruptions. Supply reliability becomes more valuable than minor price differences.

Scenario 3: Premium workflow product

A supplier combines standardized concentrations, barcode-ready labels, smart-pump compatibility, DEHP-free packaging, and strong service levels. The product may obtain a modest premium through hospital contracting.

Scenario 4: Manufacturing-led platform

A company uses the same validated bag, filling, and sterilization platform for heparin, insulin, electrolytes, and other high-alert injectables. The value lies in shared infrastructure and broader hospital account access.

Key Takeaways

• Heparin sodium and dextrose injection is a mature generic intravenous anticoagulant product.
• No meaningful composition-of-matter exclusivity remains for heparin sodium, dextrose, or their basic combination.
• The Orange Book is unlikely to present a broad barrier, but product-specific listings and container patents require review.
• The product is not a conventional biosimilar opportunity.
• Quality, sourcing, sterile manufacturing, and supply reliability are stronger barriers than active-ingredient patents.
• The most attractive excipient strategy is a simple, preservative-free, stable formulation with validated container compatibility.
• Commercial differentiation is strongest in ready-to-use bags, DEHP-free materials, standardized concentrations, barcode integration, and dependable supply.
• Generic launch risk is high because the market is mature and hospital purchasers are price-sensitive.
• Revenue exposure should be modeled through institutional volume, contracting, shortage conditions, and portfolio synergies.
• Patent strength is weak for the drug substance and basic formulation, but moderate for specialized packaging, devices, and process technology.

FAQs

Is heparin sodium in dextrose a generic drug?

Yes. The active ingredients and basic intravenous formulation are mature technologies. Product-specific FDA approval, sterile manufacturing capability, and reference-product requirements still apply.

Can a manufacturer patent a new heparin sodium concentration?

Possibly, but a concentration alone is unlikely to provide strong protection unless paired with a non-obvious technical effect, improved stability, a specific clinical advantage, or a novel delivery system.

Does dextrose improve heparin anticoagulant activity?

No. Dextrose is primarily the infusion vehicle. It does not create the anticoagulant activity of the product.

Is heparin sodium in dextrose subject to biosimilar substitution?

No. The principal pathway is generic or follow-on injectable approval rather than biosimilar substitution.

What is the highest-value commercial differentiation?

The strongest opportunities are supply reliability, ready-to-use standardized bags, low-extractables packaging, preservative-free and DEHP-free presentations, clear labeling, and compatibility with hospital infusion workflows.

References

1. DailyMed. (n.d.). Heparin sodium in 5% dextrose injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2008). Heparin sodium injection: Information for healthcare professionals. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/heparin-sodium-injection

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

5. U.S. Food and Drug Administration. (2024). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/

6. United States Pharmacopeia. (2024). Heparin sodium monograph. In United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.